Forward Texas: TAMEST Conversations on COVID-19
Treatment and Vaccine Development

Maria Elena Bottazzi PhD FASTMH
Associate Dean and Professor
Co-Section Head, Pediatric Tropical Medicine
Co-Director, Texas Children’s Center for Vaccine Development

Leading the development and testing of low-cost and effective vaccines against emerging and neglected tropical diseases
Many platforms are not currently the basis for licensed vaccines

For some platforms, adjuvants are proprietary

Public information on the specific SARS-CoV-2 antigen(s) used is limited

Need several to suited to specific population subtypes

• elderly
• children
• pregnant women or
• immunocompromised patients

Goal: A harmonized and collaborative approach for
• clinical testing (Phase 3 onwards)
• scale-up
• distribution

More than one effective vaccine (drug) approach likely will be required

Studies conducted in parallel to generate essential safety and efficacy data and accelerate the licensure and distribution

NIH to facilitate collaborations with discussions on trial designs and data sharing between government, academics industry, and funders

The Rest of the World - A Commitment to Global Access

Equitable global access to innovative tools for COVID-19 for all

Unprecedented level of partnership

Create a strong unified voice to maximize impact

Build on past experiences towards achieving this objective

Accountable to the world, to communities, and to one another.

ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR

A Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines

COMMITTMENT and CALL TO ACTION

Our Vision and Mission
Grounded in a vision of a planet protected from human suffering and the devastating social and economic consequences of COVID-19, we, an initial group of global health actors (BMGF, CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust, WHO) and private sector partners and other stakeholders, are launching

- A landmark, global and time-limited campaign that will start on 4 May 2020.

- We ask the global community and political leaders to provide the necessary resources to accelerate achievement of the shared aims.

- We support this landmark collaboration, and for donors to

Our Mission is not only accelerated development and availability of new COVID-19 tools – it is to accelerate equitable global access to safe, quality, effective, and affordable COVID-19 diagnostics, therapeutics and vaccines, and thus to ensure that in the fight against COVID-19, no one is left behind.

Aligning to Achieve Global Access

SARS CoV RBD
RBD219-N1
- cGMP Manufactured in 2016
- "Shovel ready" start of phase 1 clinical trial Q3 2020
- Investigational vaccine recommended for outbreak use in 2021

SARS CoV2 RBD
- cGMP manufacture targeted for Q3 2020
- Start of phase 1 clinical trial 2021
- Investigational vaccine recommended for outbreak use in 2022, possibly earlier

TRUSTED COLLABORATIONS
STRICT COMPLIANCE

Developing Countries Vaccine Manufacturers Network

New York Blood Center
utmb Health
WRAIR
IDRI

Baylor College of Medicine
Texas Children's Hospital
PATH

Working together to work wonders.